New ABPA Study Medication

Trial Objective

New ABPA Study MedicationThis study is looking at the effectiveness of different doses of investigational medication itraconazole for adults with asthma and allergic bronchopulmonary aspergillosis (ABPA). Itraconazole is an antifungal medication in powder form that is inhaled directly into the lungs. We are studying this medication to see if it is more effective than oral medication.

Enrollment

New enrollment for this trial is temporarily paused

Who Can Participate

Non-smoking adults diagnosed with asthma and ABPA

Age: 18-75    Gender: Any Gender


Estimated Time Commitment

Up to 9 weeks for study treatment, with 8 clinic visits - 3 of which are full day visits



Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Allen Stevens

Allen Stevens
303.398.1443

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Pulmatrix

Principal Investigators

Co-Investigators


Request More Information

Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at www.njhealth.org/coronavirus.


*
*
*
*